Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Harrow Inc HROW

Healthcare Drug Manufacturers - Specialty & Generic
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

GlobeNewswire 1 day ago

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

GlobeNewswire March 24, 2026

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

GlobeNewswire March 24, 2026

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

GlobeNewswire March 18, 2026

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

GlobeNewswire March 4, 2026

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

GlobeNewswire March 3, 2026

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

GlobeNewswire March 2, 2026

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

GlobeNewswire February 18, 2026

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack(TM) Kits

GlobeNewswire February 17, 2026

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270-$280 Million, Marking Another Year of Strong Growth

GlobeNewswire February 2, 2026

Harrow to Present at Two Investor Conferences in December

GlobeNewswire November 24, 2025

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

GlobeNewswire November 18, 2025

Harrow Announces Third Quarter 2025 Financial Results

GlobeNewswire November 10, 2025

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

GlobeNewswire October 27, 2025

ImprimisRx Announces Leadership Changes

GlobeNewswire October 6, 2025

Harrow to Acquire Melt Pharmaceuticals

GlobeNewswire September 26, 2025

Harrow Launches Harrow Access for All (HAFA)

GlobeNewswire September 25, 2025

Harrow Announces Agenda and Speakers for Investor & Analyst Day

GlobeNewswire September 15, 2025

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

GlobeNewswire September 8, 2025

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

GlobeNewswire September 8, 2025

Podcasts